Howard L. Kaufman, M.D.
Chief Medical Officer
Dr. Howard L. Kaufman joined Replimune as Chief Medical Officer in September of 2017 after having been a leading academic studying tumor immunotherapy and the optimization of viral vectors for the treatment of cancer. Most recently, Howard was Chief Surgical Officer and Associate Director for Clinical Science of the Rutgers Cancer Institute of New Jersey. He previously held appointments at Columbia University and Rush University. His academic research laboratory greatly contributed to the understanding of how viruses induce systemic immune responses. Dr. Kaufman has published over 400 peer-reviewed scientific papers, books, and review articles and serves on the editorial board of the Journal for Immunotherapy of Cancer. He is the Editor-In-Chief of the Journal of Targeted Therapies in Cancer and a Senior Associate Editor at the Journal of Translational Medicine. He is a member of numerous professional societies and is past President of the Society for Immunotherapy of Cancer (SITC). Howard received his medical degree from Loyola University, completed general surgery residency at Boston University and fellowship training in Tumor Immunology and Surgical Oncology at the NCI.